MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Envista Holdings Corporation Interest Expense 2011-2026 | NVST
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Envista Holdings Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.3 M | -100 K | -23 M | 3.1 M | 54.1 M | 62.5 M | 3.5 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 62.5 M | -23 M | 14 M |
Quarterly Interest Expense Envista Holdings Corporation
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.4 M | -700 K | - | 600 K | -1.1 M | 100 K | - | -32.1 M | 7.1 M | 16.7 M | - | 11.6 M | 6.4 M | 5.9 M | - | 12 M | 13.6 M | 18 M | - | 23.4 M | 14.5 M | 3.3 M | - | 200 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 23.4 M | -32.1 M | 5.66 M |
Interest Expense of other stocks in the Medical instruments industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
149 | - | - | $ 810 M |  USA |
 |
iRhythm Technologies
IRTC
|
5.44 M | $ 122.35 | 0.73 % | $ 3.92 B | USA |
 |
Alcon
ALC
|
204 M | $ 75.8 | -0.08 % | $ 40.4 B |  Schweiz |
 |
Repro Med Systems
KRMD
|
9.91 K | $ 3.96 | -0.75 % | $ 183 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
-26 K | $ 10.99 | 1.48 % | $ 26.7 M | USA |
 |
The Cooper Companies
COO
|
-16.4 M | $ 64.42 | -0.82 % | $ 12.8 B | USA |
 |
Haemonetics Corporation
HAE
|
-9.75 M | $ 59.93 | 0.52 % | $ 3.02 B | USA |
 |
electroCore
ECOR
|
14.9 K | $ 6.18 | -0.08 % | $ 52.4 K | USA |
 |
ICU Medical
ICUI
|
93.3 M | $ 124.82 | 0.22 % | $ 3.08 B | USA |
 |
Isoray
ISR
|
2 K | - | 0.03 % | $ 108 M | USA |
 |
Pulse Biosciences
PLSE
|
-52 K | $ 23.02 | -5.07 % | $ 1.55 B | USA |
 |
Glaukos Corporation
GKOS
|
13.6 M | $ 121.48 | 0.5 % | $ 5.88 B | USA |
 |
Microbot Medical
MBOT
|
2 K | $ 2.2 | 0.92 % | $ 101 M |  Israel |
 |
STAAR Surgical Company
STAA
|
2.25 M | $ 25.67 | 3.34 % | $ 1.27 B | USA |
 |
STERIS plc
STE
|
8.4 M | $ 221.8 | -0.77 % | $ 21.9 B | USA |
 |
Masimo Corporation
MASI
|
300 K | $ 178.63 | -0.04 % | $ 9.52 B | USA |
 |
Milestone Scientific
MLSS
|
126 K | $ 0.32 | -1.27 % | $ 26.3 M | USA |
 |
InfuSystem Holdings
INFU
|
1.4 M | $ 10.34 | 0.68 % | $ 214 M | USA |
 |
Stereotaxis
STXS
|
2 K | $ 1.93 | -1.53 % | $ 176 M | USA |
 |
Merit Medical Systems
MMSI
|
-2.39 M | $ 68.58 | -0.04 % | $ 4.06 B | USA |
 |
Teleflex Incorporated
TFX
|
57 M | $ 136.56 | -0.07 % | $ 6.09 B | USA |
 |
Utah Medical Products
UTMD
|
-120 K | $ 67.17 | -1.03 % | $ 218 M | USA |
 |
West Pharmaceutical Services
WST
|
-1 M | $ 306.16 | -1.14 % | $ 22.1 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
24 M | $ 11.91 | 0.08 % | $ 2.37 B | USA |
 |
Retractable Technologies
RVP
|
227 K | $ 0.65 | 0.2 % | $ 19.5 M | USA |
 |
Pro-Dex
PDEX
|
533 K | $ 52.1 | 2.24 % | $ 171 M | USA |
 |
LeMaitre Vascular
LMAT
|
5.18 M | $ 113.45 | 0.49 % | $ 2.57 B | USA |
 |
Predictive Oncology
POAI
|
3 | - | - | $ 31.1 M | USA |
 |
BioLife Solutions
BLFS
|
497 K | $ 21.38 | -1.57 % | $ 985 M | USA |
 |
Baxter International
BAX
|
290 M | $ 18.16 | -1.39 % | $ 9.32 B | USA |
 |
ResMed
RMD
|
3.2 M | $ 219.85 | 0.15 % | $ 32.1 B | USA |
 |
AtriCure
ATRC
|
683 K | $ 29.28 | 3.79 % | $ 1.4 B | USA |
 |
Harvard Bioscience
HBIO
|
-2.66 M | $ 6.86 | 1.18 % | $ 305 M | USA |
 |
AngioDynamics
ANGO
|
4.94 M | $ 11.1 | -0.89 % | $ 453 M | USA |
 |
Becton, Dickinson and Company
BDX
|
613 M | $ 152.14 | -1.74 % | $ 43.8 B | USA |
 |
Nephros
NEPH
|
2 K | $ 2.87 | 1.06 % | $ 29.8 M | USA |
 |
OraSure Technologies
OSUR
|
229 K | $ 3.0 | -1.64 % | $ 220 M | USA |
 |
Repligen Corporation
RGEN
|
8.12 M | $ 117.6 | 3.1 % | $ 6.55 M | USA |